BiondVax Pharmaceuticals, developer of the M-001 universal influenza vaccine candidate, has relocated to a newly constructed mid-size commercial scale manufacturing facility in Jerusalem, Israel.

“BiondVax’s new facility is custom-built for GMP manufacturing of our innovative flu vaccine candidate, which can be produced year-round and is designed to provide broad protection against influenza,” said Shimon Hassin, chief operating officer, BiondVax. “As BiondVax moves into this next exciting stage, I would like to thank our partners at Biopharmax for the design and construction of our new facility.”

Based in the Jerusalem Bio Park, a biotech hub on the Hadassah Medical Center Hebrew University Ein Kerem campus, the new approximately 20,000 square foot facility includes offices, laboratories, and GMP manufacturing suites with potential annual capacity of 40 million doses of M-001 in bulk with up to 20 million single dose syringes.